HIV Infections Clinical Trial
Official title:
Increasing Animal Source Foods in Diets of HIV-Infected Kenyan Women and Their Children
Many of the 28 million people with immunodeficiency virus (HIV) and acquired
immunodeficiency syndrome (AIDS) estimated to be living in sub-Saharan Africa also suffer
from malnutrition. Reproductive age women, their infants and young children are among the
most vulnerable for malnutrition and progression of HIV to AIDS and mortality is increased
in the malnourished, as seen in Eastern and Southern Africa. The HIV Nutrition Project (HNP)
research evaluates the effect of protein and micronutrients in meat on the health and
nutritional well being of Kenyan women living with HIV in rural Kenya and the health and
development of their children, by means of a randomized nutrition intervention. We will
determine if meat in the diets of HIV- infected women and their children (1) protects the
immune system and prevents severe infection, (2) prevents the loss of body mass and enhances
the quality of life among drug naïve women not yet ill enough to warrant antiretroviral
drugs and (3) positively impacts growth and development of vulnerable children of the
HIV-infected women when compared to those given supplements with the same amount of energy
but with either soya or wheat protein. The intervention food with beef protein provides
significant vitamin B12, lysine and bio-available iron, zinc and selenium when compared to
the soya and wheat supplements. Deficiencies of these nutrients may hasten HIV disease
progression.
The findings from our project may have implications for the development of initiatives that
are either sustainable or subsidized by the local, regional and/or global economies that
ensure that all HIV-infected individuals have access to adequate nutrition support that
includes foods that provide enough nutrients that are needed to optimize health and
well-being. The knowledge gained may significantly impact other populations at high risk for
decreased immune function such as those with tuberculosis and malaria.
This is a 3 arm randomized design where 225 HIV-infected rural Kenyan mothers with a CD4
between 250 and 500, WHO Stage 1 or 2, and with no co-existing infections, receive with
their child, a nutrition biscuit supplement daily (5 days/week) for 12 months. These women
are not yet ill enough to warrant treatment with antiretroviral drugs in Kenya and therefore
a food intervention may keep them healthy longer and delay the need for drugs.
n/a
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
| Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
| Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
| Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
| Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
| Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
| Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
| Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
| Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
| Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
| Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
| Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
| Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
| Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
| Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
| Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
| Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
| Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
| Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
| Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |